HSBC upgrades Biogen (BIIB $45.50) to Overweight from Neutral and raises their tgt to $68 from $51 saying the outcome of the Advisory was better than they expected suggesting their prior base case assumptions for Tysabri's return is too low

Biogen Idec: Susquehanna comments on Tysabri decision (BIIB) 45.50 : Susquehanna notes that yesterday afternoon, an FDA advisory committee voted unanimously to recommend a return to market for Tysabri as a treatment for relapsing multiple sclerosis. Firm was surprised by the panel's leniency towards widely anticipated labeling restrictions and monitoring requirements. They say there was an emphasis was placed on clinical vigilance, and they speculate whether the broader community neurologist shares such a similar viewpoint. Firm anticipates the FDA will follow the panel's recommendation and approve the drug by its PDUFA data (March 29) although there is a chance that additional time may be required to refine some the elements of the patient monitoring program. They estimate peak sales of Tysabri could approach $750 mln, however, at this point with no knowledge on the finer points of final risk mgmt plan to be implemented, they believe BIIB shares are fairly valued. They don't expect initial sales to surpass current bullish expectations (>$100 mln). Maintains Neutral.

SFCC
3/9/2006 8:20:08 AM SFBC International Inc. (SFCC) reported fourth quarter EPS of $0.42 after the close on Wednesday, compared to the $0.40 reported last year. The consensus estimate was for EPS of $0.40. The company expects to report full year 2006 EPS of $1.52 to $1.66, compared to the consensus estimate of $1.75. The stock is now up 4.47 on 10K shares Thursday morning on Inet.

HSBC upgrades Biogen (BIIB $45.50) to Overweight from Neutral and raises their tgt to $68 from $51 saying the outcome of the Advisory was better than they expected suggesting their prior base case assumptions for Tysabri's return is too low

Biogen Idec: Susquehanna comments on Tysabri decision (BIIB) 45.50 : Susquehanna notes that yesterday afternoon, an FDA advisory committee voted unanimously to recommend a return to market for Tysabri as a treatment for relapsing multiple sclerosis. Firm was surprised by the panel's leniency towards widely anticipated labeling restrictions and monitoring requirements. They say there was an emphasis was placed on clinical vigilance, and they speculate whether the broader community neurologist shares such a similar viewpoint. Firm anticipates the FDA will follow the panel's recommendation and approve the drug by its PDUFA data (March 29) although there is a chance that additional time may be required to refine some the elements of the patient monitoring program. They estimate peak sales of Tysabri could approach $750 mln, however, at this point with no knowledge on the finer points of final risk mgmt plan to be implemented, they believe BIIB shares are fairly valued. They don't expect initial sales to surpass current bullish expectations (>$100 mln). Maintains Neutral.

3/9/2006 8:09:33 AM We alerted readers at 4:52 that Hansen Natural Corp. (HANS) reported fourth quarter EPS of $0.75, compared to the $0.31 reported last year. The consensus estimate was for EPS of $0.62. Revenues increased to $98 million, from the $50.3 million reported last year. The stock is now up 10.51 on 13K shares Thursday morning on Inet

3/9/2006 8:09:33 AM We alerted readers at 4:52 that Hansen Natural Corp. (HANS) reported fourth quarter EPS of $0.75, compared to the $0.31 reported last year. The consensus estimate was for EPS of $0.62. Revenues increased to $98 million, from the $50.3 million reported last year. The stock is now up 10.51 on 13K shares Thursday morning on Inet